| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
|
Llanos-Cuentas, Alejandro
|
|
|
18 |
8 |
p. 874-883
|
artikel
|
| 2 |
Bloodstream infection and occlusion of central venous catheters in children
|
Rickard, Claire M
|
|
|
18 |
8 |
p. 815-817
|
artikel
|
| 3 |
Clinical bacteriology in low-resource settings: today's solutions
|
Ombelet, Sien
|
|
|
18 |
8 |
p. e248-e258
|
artikel
|
| 4 |
Corrections
|
|
|
|
18 |
8 |
p. 829
|
artikel
|
| 5 |
Corrections
|
|
|
|
18 |
8 |
p. 829
|
artikel
|
| 6 |
Corrections
|
|
|
|
18 |
8 |
p. 829
|
artikel
|
| 7 |
Diagnosis, treatment, and control of scabies: can we do better?
|
Engelman, Daniel
|
|
|
18 |
8 |
p. 822-823
|
artikel
|
| 8 |
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria
|
Bélard, Sabine
|
|
|
18 |
8 |
p. 819-820
|
artikel
|
| 9 |
Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection)
|
Anderson, Deverick J
|
|
|
18 |
8 |
p. 845-853
|
artikel
|
| 10 |
Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial
|
Barda, Beatrice
|
|
|
18 |
8 |
p. 864-873
|
artikel
|
| 11 |
Enhanced terminal room disinfection and the need for multimodal collaboration
|
Crotty, Matthew P
|
|
|
18 |
8 |
p. 814-815
|
artikel
|
| 12 |
Enterovirus D68 and acute flaccid myelitis—evaluating the evidence for causality
|
Messacar, Kevin
|
|
|
18 |
8 |
p. e239-e247
|
artikel
|
| 13 |
Evidence sources on the natural history of latent tuberculosis infection
|
Menzies, Nicolas A
|
|
|
18 |
8 |
p. 834-835
|
artikel
|
| 14 |
Following the roadmap toward an effective Ebola virus treatment
|
Racine, Trina
|
|
|
18 |
8 |
p. 820-822
|
artikel
|
| 15 |
Highlights from ASM Microbe 2018
|
Sekkides, Onisillos
|
|
|
18 |
8 |
p. 839
|
artikel
|
| 16 |
HIV criminalisation laws in the USA: built on phobias or facts?
|
Balakrishnan, Vijay
|
|
|
18 |
8 |
p. 843
|
artikel
|
| 17 |
Host and viral genetic diversity can help explain mortality during the 1918–21 influenza pandemic in the Pacific region
|
Tarantola, Arnaud
|
|
|
18 |
8 |
p. 833-834
|
artikel
|
| 18 |
Host and viral genetic diversity can help explain mortality during the 1918–21 influenza pandemic in the Pacific region – Authors' reply
|
Shanks, G Dennis
|
|
|
18 |
8 |
p. 834
|
artikel
|
| 19 |
HRP-2 deletion: a hole in the ship of malaria elimination
|
Verma, Anil Kumar
|
|
|
18 |
8 |
p. 826-827
|
artikel
|
| 20 |
ICD-11: in praise of good data
|
The Lancet Infectious Diseases,
|
|
|
18 |
8 |
p. 813
|
artikel
|
| 21 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
18 |
8 |
p. 841
|
artikel
|
| 22 |
Interpretation of the switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10 in Belgium
|
Izurieta, Patricia
|
|
|
18 |
8 |
p. 831-832
|
artikel
|
| 23 |
Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission
|
Hui, David S
|
|
|
18 |
8 |
p. e217-e227
|
artikel
|
| 24 |
Moxidectin for deworming: from trials to implementation
|
Maheu-Giroux, Mathieu
|
|
|
18 |
8 |
p. 817-819
|
artikel
|
| 25 |
New challenges to eradicating Guinea worm disease
|
Dumiak, Michael
|
|
|
18 |
8 |
p. 838
|
artikel
|
| 26 |
Ocular tuberculosis masquerading as a tumor
|
Sassalos, Thérèse M
|
|
|
18 |
8 |
p. 924
|
artikel
|
| 27 |
Prevalence of drug-resistant tuberculosis in South Africa
|
André, Emmanuel
|
|
|
18 |
8 |
p. 835-836
|
artikel
|
| 28 |
Prevalence of drug-resistant tuberculosis in South Africa
|
Mahla, Ranjeet Singh
|
|
|
18 |
8 |
p. 836
|
artikel
|
| 29 |
Prevalence of drug-resistant tuberculosis in South Africa – Authors' reply
|
Ismail, Nazir A
|
|
|
18 |
8 |
p. 836-837
|
artikel
|
| 30 |
Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions
|
Menzies, Nicolas A
|
|
|
18 |
8 |
p. e228-e238
|
artikel
|
| 31 |
Reappraising the cardiosafety of dihydroartemisinin-piperaquine
|
Millat-Martínez, Pere
|
|
|
18 |
8 |
p. 824-826
|
artikel
|
| 32 |
Research brief
|
Mohammadi, Dara
|
|
|
18 |
8 |
p. 842
|
artikel
|
| 33 |
Resurgence of scarlet fever in China: a 13-year population-based surveillance study
|
Liu, Yonghong
|
|
|
18 |
8 |
p. 903-912
|
artikel
|
| 34 |
Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis
|
Chan, Xin Hui S
|
|
|
18 |
8 |
p. 913-923
|
artikel
|
| 35 |
Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study
|
Sivapalasingam, Sumathi
|
|
|
18 |
8 |
p. 884-893
|
artikel
|
| 36 |
Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes
|
Cassell, Jackie A
|
|
|
18 |
8 |
p. 894-902
|
artikel
|
| 37 |
Short-term and mid-term solutions for influenza vaccines
|
Hanon, Emmanuel
|
|
|
18 |
8 |
p. 832-833
|
artikel
|
| 38 |
Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?
|
Desmet, Stefanie
|
|
|
18 |
8 |
p. 830-831
|
artikel
|
| 39 |
The resurgence of scarlet fever in China
|
Zhang, Xingyu
|
|
|
18 |
8 |
p. 823-824
|
artikel
|
| 40 |
The USA's HIV problem
|
Burki, Talha
|
|
|
18 |
8 |
p. 840-841
|
artikel
|
| 41 |
Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial
|
Wolf, Joshua
|
|
|
18 |
8 |
p. 854-863
|
artikel
|
| 42 |
WHO preferred product characteristics for new vaccines against tuberculosis
|
Schrager, Lewis K
|
|
|
18 |
8 |
p. 828-829
|
artikel
|
| 43 |
Why do parents not want to vaccinate their children?
|
De Ambrogi, Marco
|
|
|
18 |
8 |
p. 844
|
artikel
|
Tijdschrift beschrijving